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Abstract
Recent findings related to childhood leukaemia incidence near nuclear 
installations have raised questions which can be answered neither by current 
knowledge on radiation risk nor by other established risk factors. In 2012, 
a workshop was organised on this topic with two objectives: (a) review of 
results and discussion of methodological limitations of studies near nuclear 
installations; (b) identification of directions for future research into the causes and 
pathogenesis of childhood leukaemia. The workshop gathered 42 participants 
from different disciplines, extending widely outside of the radiation protection 
field. Regarding the proximity of nuclear installations, the need for continuous 
surveillance of childhood leukaemia incidence was highlighted, including a 
better characterisation of the local population. The creation of collaborative 
working groups was recommended for consistency in methodologies and the 
possibility of combining data for future analyses. Regarding the causes of 
childhood leukaemia, major fields of research were discussed (environmental 
risk factors, genetics, infections, immunity, stem cells, experimental research). 
The need for multidisciplinary collaboration in developing research activities 
was underlined, including the prevalence of potential predisposition markers 
and investigating further the infectious aetiology hypothesis. Animal studies 
and genetic/epigenetic approaches appear of great interest. Routes for future 
research were pointed out.
Keywords: childhood, leukaemia, risk, nuclear installations, aetiology,  
epidemiology
1. Introduction
Leukaemia is the commonest type of childhood malignancy, accounting for ~30% of all 
 diagnoses in children less than 15 years of age in economically developed regions of the 
world. The heterogeneous nature of leukaemia is well established. In childhood, the major 
subtypes are acute lymphoblastic leukaemia (ALL) and acute myeloid leukaemia (AML) with 
ALL occurring approximately five times more frequently than AML [1, 2]; chronic myeloid 
leukaemia (CML) also occurs rarely. Acute leukaemia can be further classified into distinct 
subtypes according to cell lineage, stage of immunophenotypic maturation and specific molec-
ular genetic abnormalities [3]. Of these, B-cell-precursor ALL is the commonest subtype. In 
contrast to other subtypes like T-cell ALL or AML, its incidence has a distinct age peak in 
children aged two to five years [4].
Many factors have been proposed to be causative of childhood leukaemia [5–7]. However, 
to date, the only established risk factors for childhood leukaemia are Down syndrome, sex 
(with boys more often affected than girls, with a ratio ~1.2 : 1), chemotherapeutic drugs and 
acute exposure to ionising radiation at moderate and high doses (above 100 mSv). Several 
studies suggested that risk may exist at lower radiation doses and dose rates, and that this 
risk is compatible with current predictions [8–11]. In 1990, the hypothesis of hereditary 
radiation effects on childhood leukaemia risk was proposed by Gardner et al to explain 
the Sellafield cluster [12], but consecutive negative studies lead to the rejection of this 
hypothesis [13, 14]. Exposure to 50 Hz electric and magnetic fields (ELF-EMF) is also 
suggested as a risk factor for childhood leukaemia [15], but there is as yet no biological 
evidence supporting the epidemiological evidence [16]. There is consistent evidence from 
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epidemiological studies that high birth weight is a determinant of disease risk [17–19]. The 
role of exposure to infectious agents and immune function in relation to risk of childhood 
ALL is also under  investigation [20, 21], but the mechanisms by which these factors could 
play a role are still not clear.
Living near a nuclear facility became a suspected risk factor for childhood leukaemia 
after the 1984 report on an increased leukaemia risk in the village of Seascale close to the 
British nuclear fuel reprocessing plant of Sellafield [22]. Since then, a number of studies 
have investigated the leukaemia risk near nuclear facilities, including nuclear power plants 
(NPPs), and several reviews were published [23–25]. Between 2008 and 2011, several meet-
ings were held and several committees were convened to review existing results of cancer 
risks around nuclear facilities and provide recommendations, e.g. in Germany [7, 26], in 
France [27], in Sweden [28] and in the UK [29]. Based on the recommendations from these 
meetings, the German Federal Office for Radiation Protection (BfS) and the French Institute 
for Radiological Protection and Nuclear Safety (IRSN) decided to organise a focused work-
shop on the topic of future research on childhood leukaemia, bringing together researchers 
from a wide range of related disciplines. This workshop was organised under the auspices of 
the Multidisciplinary European Low Dose Initiative (MELODI, www.melodi-online.eu) and 
was held in France in June 2012. The Workshop had two aims: (a) to review the latest results 
and to discuss methodological limitations of studies of childhood leukaemia incidence close 
to nuclear installations; and (b) to identify new directions for future research into the causes 
and pathogenesis of leukaemia in children. Thus, the Workshop did not just cover the effect 
of radiation-related leukaemia risk, but also other major known or suspected risk factors of 
childhood leukaemia.
This paper summarises the results of the Workshop. Its first part deals with the issue of 
childhood leukaemia risk near nuclear installations and focuses on a review of available find-
ings, the design of epidemiological studies and suggested improvements for the future. The 
second part concerns the aetiology of childhood leukaemia and the underlying disease biology 
(B-cell development and haematopoietic stem cells (HSCs)), environmental, infectious and 
genetic risk factors and the relevance of animal models. Recommendations are then detailed.
2. Studies of childhood leukaemia risk near nuclear installations
A major aspect of the Workshop was to discuss the current hypothesis regarding an excess 
risk of childhood leukaemia near nuclear installations. Participants provided an overview of 
studies undertaken in Europe in recent years and of those planned in the United States. Special 
attention was paid to leukaemia risk in the youngest age group. Due to the diversity of epi-
demiological designs and analysis methods, methodological aspects of recent studies were 
considered.
2.1. Review of current knowledge about the risk of childhood leukaemia near  
nuclear  installations
Based on a combination of several criteria (statistical significance, validity of the methodol-
ogy, confirmation by different authors using different approaches and persistence over time), 
the Workshop participants agreed that there is convincing evidence for three confirmed clus-
ters of childhood leukaemia near nuclear installations: these are near the Sellafield reprocess-
ing plant in Cumbria, England; the Dounreay reprocessing plant in Northern Scotland; and 
the Kruemmel NPP in Northern Germany [23]. However, leukaemia clusters also have been 
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reported elsewhere and are not specific to nuclear installations. For example, the Fallon cluster 
in Churchill County, Nevada, is a striking example of a leukaemia cluster [30]: 14 children 
were diagnosed with ALL during the period 1997–2003 while only three to four cases were 
expected. Despite the comprehensive public health investigation launched by the US Centers 
for Disease Control and Prevention (CDC) the cause of the cluster remains unknown.
Several reviews of childhood leukaemia risks near nuclear installations already exist 
 [23–25, 31, 32], as well as a meta-analysis [33], which has been criticised due to doubts over 
the validity of the selection process and potential publication bias [29, 34, 35]. The review of 
results from multisite studies was updated during the Workshop by considering studies about 
childhood leukaemia risk near NPPs published after 2008 (Germany [36, 37], Switzerland [38], 
France [39, 40], Finland [41], Great Britain [29] and Belgium [42]). Consistent with other 
authors [43], the Workshop participants noted that, even when the associations are not sta-
tistically significant, the results from these recent studies demonstrated some elevated risk of 
childhood leukaemia when considering the 0–4-year age category within 5 km from a NPP. 
However, results are based on small numbers, and considerable methodological differences 
between studies (design, statistical analyses, periods covered, diagnosis quality and adminis-
trative units analysed) do not allow the combination of their results by simply adding numbers. 
Moreover, a compilation of results available for the complementary 5–14 year age category 
performed during the Workshop did not indicate an elevated risk of childhood leukaemia in 
this age category.
Based on the available literature, the Workshop participants concluded that there was no 
elevated risk of childhood leukaemia globally near NPPs in children less than 15 years old.
The rather consistent pattern of increased leukaemia risk in the 0–4-year olds needs to be 
verified in the future and should not be interpreted as a causal association, but it may provide 
clues about a possible link between childhood leukaemia and living in the close proximity of 
a nuclear facility (see [44]).
Two new studies have been published since the Workshop. The first one considered can-
cer incidence within 25 km of the three Ontario NPPs using an ecological study design [45]. 
The second is a case–control study including all leukaemia and non- Hodgkin lymphoma 
cases diagnosed below age five years in Great Britain, and analysing risk related to dis-
tance from 13 NPPs [46]. Both studies showed no excess risks near NPPs. Nevertheless, 
as in previous studies, the numbers of cases were small when focusing on the 0–4 year 
age category within 5 km of the NPPs. The US National Research Council (NRC) recently 
published a report on the assessment of cancer risks in populations near US nuclear facil-
ities  [47]. The NRC committee recommended considering two different study designs: 
(1) an ecologic study of multiple cancer types of populations living near nuclear facili-
ties and (2) a record-linkage-based case–control study of cancers in children born near 
nuclear facilities. Testing the feasibility of a dose assessment was also recommended. The 
launch of a pilot study, based on seven nuclear installations located in six US states, was 
announced in October 2012.
2.2. Methodological aspects of studies performed
2.2.1. Epidemiological design. Most of the studies performed since the early 1980s have been 
of ecological design (i.e. average rates in geographical areas). This type of analysis can be 
subject to well-known types of bias (ecological fallacy, migration, sensitivity to the arbitrary 
choice of the study perimeter, etc). Thus, more recent studies used individual based designs, 
i.e. case–control [36, 40] and cohort design [38, 41]. Whilst these approaches can avoid some 
of the limitations associated with ecologic study design, other limitations exist (selection bias, 
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participation bias, migration bias, lack of control of confounding factors, small sample size, 
etc). Furthermore, response bias specific to case–control studies is well documented [48, 49]. 
Indeed, at the German KiKK study data from a detailed questionnaire were not used due to the 
potential response bias [36]. Nevertheless, if the geographic unit used in an ecologic study is small 
enough (for example municipalities in France), results from case–control and ecologic studies 
are in agreement [36, 37, 40]. In conclusion, for the specific question of childhood leukaemia 
incidence near NPPs, no clear preference is evident; each design presents advantages and limi-
tations. Future study protocols have to be developed according to the availability of data, the 
input required versus the scientific return and the hypotheses to be tested, with specific atten-
tion paid to minimise potential biases. Notwithstanding this, efforts to evaluate the feasibility 
of combining data from different existing studies to increase statistical power might be useful.
2.2.2. Power and prior hypothesis. The Workshop participants underlined the necessity for a 
continuing surveillance of childhood leukaemia incidence near NPPs, but not limited to NPPs. 
Nevertheless, they recommended that no new studies are set up before an explicit hypothesis 
is formulated. The main analysis to test this hypothesis must be specified, and the associated 
statistical power must be calculated a priori (which is not systematically done in the usual 
practice). Multisite studies are preferred to single-site studies, as they have a greater statisti-
cal power and provide a broader context for the interpretation of results, i.e. comparing risks 
between sites of similar characteristics.
Large-scale studies, not focused on potential sources of risk, are useful with respect to the 
question of whether childhood leukaemia has the tendency to cluster. Hitherto, results are not 
consistent (e.g. [50–53]). The issue of clustering is important for the interpretation of local 
clusters (in particular with respect to the infection hypothesis) and should be investigated 
further, but independently from the existence of nuclear sites. It was also concluded that new 
studies on childhood leukaemia near nuclear installations should aim to look at other potential 
causes of leukaemia.
2.2.3. Pertinent outcomes. The Workshop participants agreed that it was reasonable for 
studies near nuclear sites to have considered childhood leukaemia as the main potential 
outcome; but given the heterogeneity of the diseases collectively described as ‘leukaemia’, 
future studies should distinguish between leukaemia subtypes. Combined analyses of data 
from several countries in Europe may allow the accumulation of a sufficiently large number 
of cases for such subtype-specific analyses. Further, the unclear and somewhat arbitrary (at 
least, historically) distinction between some forms of childhood NHL and some forms of 
childhood ALL must be borne in mind.
Other outcomes may be considered, but only if they are clearly hypothesis-driven. For exam-
ple, the Belgian NUCABEL study considered thyroid cancer in addition to childhood leukae-
mia, because the study was ordered following the Fleurus nuclear incident involving releases of 
iodine-131 [42]. Among pathologies that were hypothesised to be potentially associated to either 
pre-conceptional [54] or in utero exposure, congenital malformations might also be considered 
as a possible health indicator, as was done for example in Germany in parallel to the KiKK 
study [55]. It was noted that information on other diseases (especially childhood cancers other 
than leukaemia) might help with the interpretation of results in that, for example, a common 
bias could be manifest over all types of childhood cancer rather than just childhood leukaemia.
2.2.4. Exposure indicators. Distance can be easily and reliably determined, but it constitutes 
only a crude proxy for radiation exposure from nuclear installations. Better exposure indica-
tors are needed for investigating health effects around nuclear sites. This recommendation is 
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in accordance with that of the NRC report which calls for absorbed doses to individual organs 
to be estimated [47].
Based on the results from exposure monitoring or dosimetric estimates, the orders of 
 magnitude of the doses attributable to current routine discharges appear to be small. The 
so-called ‘radioecological studies’ conducted in the UK  [56–58], in Germany  [59] and in 
France [60, 61] indicated that the levels of doses attributable to releases from the plants were 
well below those due to natural sources of radiation (100 to 1000 times, or more) and could 
not explain the observed number of cases [62, 63]. The feasibility and pertinence of measure-
ments of radionuclides (tritium and carbon-14 and possibly other radionuclides) in environ-
mental media or directly in children (e.g. urine analysis), or other dosimetric approaches to 
evaluate individual doses should be investigated, as the direct measurement of the body con-
tents of radionuclides such as caesium-137 and plutonium-239/240 have provided valuable 
information in the past (e.g. [58, 64, 65]).
It is also important that the characteristics of the local population (demography, sociology, 
socio-economic status (SES), life habits, day-care attendance, etc) are determined in as much 
detail as possible. Also, attention should be given to suspected potential environmental risk 
factors for leukaemia, such as ELF-EMF, pesticides, air pollution, and proximity of a petrol 
station or industrial sites.
2.3. Routes of improvement
The Workshop participants concluded that systematic registration of childhood leukaemia 
cases is needed based on exhaustive and standardised recording systems, including popula-
tion-based registries. Continuation and development of ongoing registration activities have 
to be supported; this might include additional information to be collected in order to cap-
ture early life exposures. Reconstructing the exposure history of the children (place of birth, 
residential history, antenatal exposures, etc) is desirable, wherever possible with reasonable 
effort. Also, efforts should be made for studies to include collection of biological samples to 
support research into the pathogenesis of childhood leukaemia.
The Workshop participants encourage collaboration between teams involved in this research 
topic to bring together investigators from different studies, and control for methodological dif-
ferences, in order to better interpret and evaluate the coherence and differences of the results 
obtained in various countries. Participation in cross-border initiatives would also facilitate inves-
tigating possible health effects in the vicinity of the many nuclear sites that are located close to 
national borders, as is in the case of France and Belgium (Chooz NPP). Also, the consideration of 
several potential confounders that may lead to differences in findings among countries—e.g. SES, 
urban–rural status, population density—should be considered; but the strong overlapping of these 
factors should be kept in mind in the interpretation of the results. Finally, collaboration should 
provide the framework for an international combined analysis, which is the best approach to the 
derivation of pooled risk estimates. A working group at the European level should verify the fea-
sibility and pertinence of such pooling effort, with a special attention to minimising biases.
3. Aetiology and mechanisms of childhood leukaemia initiation 
and development
The second part of the Workshop focused on the aetiology and mechanisms of childhood 
leukaemia initiation and development, taking into account different environmental expo-
sures and genetic risk factors [5]. It is the aim of international consortia like the Childhood 
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Leukaemia International Consortium (CLIC) [66] and the International Childhood Cancer 
Cohort Consortium (I4C) [67], to pool data to further understand the causes of childhood 
leukaemia. Workshop participants provided an overview of current knowledge and identified 
possible steps forward. Specific attention was given to B-cell-precursor ALL, which is the 
commonest subtype of childhood leukaemia.
3.1. The multistep development of childhood leukaemia
Childhood leukaemia is a heterogeneous disease, and its development is a multistep process [7, 68]. 
Current results indicate that the first step occurs in utero converting a haematopoietic precur-
sor or stem-cell to a preleukaemic clone [69, 70]. Specific chromosomal translocations, as a 
result of DNA double strand break or high hyperploidy, arising probably from a single-step 
mechanism [71] are the commonest cytogenetic abnormalities in B-cell-precursor ALL. For 
example, the translocation RUNX1-ETV6 occurs with a frequency of approximately 20% 
in ALL, and high hyperploidy is found in 25–30% of ALL cases. It has been shown that 
approximately one in 100 new-borns carry the RUNX1-ETV6 translocation, which is a rate 
significantly higher than the overall incidence rate of ALL in the population [72]. This would 
imply that preleukaemic clones are frequent, and normally extinguished (or at least kept at 
bay) by natural processes. However, such high frequency of RUNX1-ETV6 translocation was 
not confirmed in another recent study [73].
Beyond the known genetic or epigenetic event(s), other elements must interact to lead to 
the development of acute leukaemia [74, 75], but so far, epidemiological studies have not been 
able to distinguish between the correlation of various potential risk factors with the initial and 
subsequent genetic events.
Efforts need to concentrate on determining the time of origin of the preleukaemic clone 
and its prevalence at birth, as this is important for the understanding of the role and pertinent 
time window at which risk factors under consideration would be involved [76]. The nature of 
the cell-of-origin cannot be identified by studying ALL samples at the time of diagnosis [77]. 
Thus, prospective designs have to be considered, and birth cohorts may prove of great interest. 
Given the rarity of the disease, a worldwide coordinated approach is needed to allow compari-
son of the prevalence of the preleukaemic clone in different countries and ethnic groups. So 
far, little is known about ALL incidence and trends in developing countries, but the incidence 
of pre-B ALL generally appears to be low in low-income and middle-income countries and 
increases substantially as countries undergo socio-economic development [78, 79].
3.2. Inherited susceptibilities
Childhood ALL arises as a consequence of a limited number of genetic alterations [80]. 
Several independent genome-wide association studies (GWAS) have confirmed a number 
of genetic variants that affect genetic susceptibility to ALL, although they are individually 
modest in their effects. In the most recent GWAS on ETV6-RUNX1-positive ALL, a few 
(ETV6-RUNX1-specific) susceptibility loci, predominantly related to pathways controlling 
embryonic and B-cell development and differentiation, were identified [81]. Based on copy 
number alterations, cases could be categorised into four distinct subgroups revealing genetic 
diversity within ETV6-RUNX1-positive ALL which is of importance for improving treatment 
strategies [82, 83]. Polymorphisms in many other pathways have been investigated in relation 
to risk of ALL such as DNA repair and cell cycle control genes [84, 85]. A meta-analysis on 
candidate genetic variations, however, saw significant associations in only eight out of 25 poly-
morphic variants [86]. GWAS revealed that common genetic variations contribute to the risk 
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of B-cell-precursor ALL [87]. On the other hand, a high concordance of subtypes of ALL 
within families has also been reported [88], indicating strong genetic and/or environmental 
risk factors are restricted to specific ALL subtypes. This implies that future studies on risk 
 factors should distinguish between ALL subtypes. Similarly, leukaemias in infants and in 
young children are different genetic and clinical entities that should be examined separately 
in future epidemiological study.
Next-generation sequencing (whole genome or transcriptome sequences, exome capture 
and sequencing, analyses of the methylome) of ALL cases might uncover a common signa-
ture. In contrast to GWAS, deep sequencing focuses on mutations and other detailed differ-
ences e.g. in the epigenome, which could, at least partly, reflect the effects of the environment. 
As for other cancers [89, 90], this could help to characterise leukaemia subgroups that might 
not show up in an overall approach, or detect common patterns/footprints possibly correlated 
to external risk factors [91–93].
3.3. Developmental aspects
Haematopoiesis in the embryo occurs in stages [94]. The first stage occurs early in intra-
uterine life and aims at producing red blood cells, whilst the second generates all lineages of 
blood cells and HSCs. During foetal life, HSCs are characterised by a high level of cell cycle 
activity (approximately 100% per 24 h) and become quiescent upon seeding the bone mar-
row, a process finalised in humans at an age of approximately two years. The properties and 
functionality of the developing haematopoietic system may prove important for the onset, but 
also for the outcome of the disease. Indeed, different age groups are associated with different 
leukaemia subtypes: MLL-related B-cell ALL is the main subtype in the age group 0–1, while 
B-cell-precursor childhood ALL peaks around 2–5 years.
Cell cycle activity of HSCs is carefully modulated by a complex network of cell-intrin-
sic and cell-extrinsic mechanisms [94] and the understanding of the age-dependent cell 
cycle regulation might, therefore, provide clues to the development of leukaemia subtypes. 
Epidemiologic studies should aim at distinguishing the leukaemia subtypes associated to dif-
ferent age categories. Animal models may give further insight into haematopoiesis in different 
age groups and on external influences on these processes.
3.4. Microenvironment
In view of the high cell division rate during foetal and infant haematopoiesis and the mutation 
potential of lymphoid cells, any genotoxic compound as well as the weakening of cell cycle 
checkpoint stringency and immunological surveillance can increase malignant transformation.
The stromal microenvironment is known to be important for HSCs’ proliferation, activity 
or quiescence, respectively, and for B-lineage development and differentiation. Leukaemia-
specific genetic aberrations have been found in the mesenchymal stem cells in some ALL 
cases [95]. Overall, the role of the microenvironment on the persistence of preleukaemic 
clones and the plasticity of leukaemia cells needs to be uncovered. In a mouse model the 
lineage fate of leukaemia cells (B-cell ALL versus AML) was determined by the host micro-
environment [96].
3.5. Immune system and the infectious hypothesis
The hypothesis that childhood leukaemia is a rare response to an infection is persistent. Kinlen 
suggested that childhood leukaemia could arise as a rare consequence of exposure to a specific 
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unidentified common infection, the rare outcome being particularly evident at times of unusual 
population mixing, when a relatively large number of susceptible children encounter a relatively 
large number of infected individuals leading to (largely subclinical) epidemics [21, 97–99]. 
It has been suggested that the construction of a nuclear facility in a rural area might promote 
unusual social contacts and population mixing that could represent at least a cofactor of the 
risk observed [98]. This infection hypothesis could also provide an explanation for the leu-
kaemia cluster in Fallon, USA [30, 100]. Greaves hypothesised that a paucity of exposure to 
infectious agents in the first year of life and subsequent ‘delayed’ infectious challenge may be 
causal in the development of B-cell-precursor ALL in the peak ages two to five years [20, 101]. 
This hypothesis is supported by studies that have looked at self-reported day-care attendance 
as proxy for social contacts [102], but other studies observed that children who developed 
B-ALL aged 2–5 years had significantly more clinically diagnosed infectious illness episodes 
in the first year of life compared to controls [103]. This suggests that immune deregulation 
in children who develop ALL may be detectable several years before diagnosis [104, 105]. 
Further support for this observation is provided by demonstrating that Interleukin 10 levels in 
neonates are reduced in new-borns who develop leukaemia [106].
The influence of infections on HSC proliferation has been shown [107], thus confirming 
a relation with infections, immune system and inflammation on a molecular basis. Further 
studies should try to include the development and status of the immune system in the foetus 
compared to infants, young children and adults.
If a specific infectious agent is responsible for childhood leukaemia then it should be 
detectable. Identification of gene variants should be possible by revisiting already available 
single-nucleotide polymorphism (SNP) data. Deep sequencing should help finding the pres-
ence of pertinent viruses or epigenetic marks of their action if there was a virus-based hit-and-
run mechanism, but it should be borne in mind that if childhood leukaemia is a rare response 
to a common infection then the responsible agent is likely to have infected most children, and 
only those in remote rural areas may have escaped infection.
3.6. Animal models
As an animal model, a ‘multi-hit’ model is highly desirable to study the mechanisms of ini-
tiating events (genetic, epigenetic or environmental hits) as well as the nature and role of 
the further hits, their kinetics and age-dependence and potential risk factors (intrinsic versus 
extrinsic factors: chemicals, radiation, infections/inflammation, immune control of malignant 
progression). For many years the existing animal models were only of limited versatility, and 
therefore the generation of new, more adequate animal models for childhood leukaemia is 
necessary [108, 109]. Mouse models can contribute in supporting hypotheses derived from 
human molecular studies, and vice versa, as for instance the contribution of gene variants or 
the identification of new (epi)genetic susceptibility genes.
The ultimate goal is to be able to mimic in the mouse the features of human B-cell ALL, at each 
level (molecule, cell, tissue, whole organism), including initiation, progression, evolution, response 
to therapy and eventual cure or relapse. Mouse models of B-cell ALL are useful for exploring the 
abnormal processes in haematopoiesis leading to leukaemia and the role of the immune system 
and for identifying fingerprints of exposure [77]. Other models, like the NOD/SCID mice, offer the 
possibility of studying premalignant human cord HSCs and follow up their development.
Additionally, the analysis of host genetic background in leukaemia development would 
give further benefits. In a well-defined mouse model the animals should be exposed to possi-
ble risk factors (radiation, chemicals, infections/inflammation, replicative stress, etc) followed 
by complete phenotyping with standardised protocols. A mouse model of controlled genetic 
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variability with a backcross between two syngeneic mouse strains (a resistant one and a sus-
ceptible one) would allow the assessment of the role of the various low-susceptibility genes.
4. Conclusions and recommendations
The Workshop participants suggested a general need for a better understanding of the causes 
of childhood leukaemia. This should also shed light in understanding childhood leukaemia 
near nuclear installations. The path forward should involve extended multidisciplinary col-
laborations to improve consistency of approaches between countries and researchers in order 
to facilitate a better understanding of the results regarding the occurrence of childhood leu-
kaemia near nuclear installations. Overall, stronger networking amongst investigators in dif-
ferent disciplines involved in research on childhood leukaemia is warranted. This should be 
done in parallel with work that focuses on as accurate as possible exposure characterisation, 
limiting confounding, measuring differential bias, and controlling selection bias. To improve 
the understanding of the existing results, further work should focus primarily on childhood 
leukaemia, though noting that studies of other diseases may help interpretation (i.e. is the 
association confined to childhood leukaemia or not?).
It was emphasised that risk factors under consideration should be analysed in relation to 
childhood leukaemia subtypes, e.g. include tumour characterisation by genetic/epigenetic 
profiles in conjunction with epidemiological data. To that extent, the re-evaluation of existing 
material (e.g. from GWAS) in view of new hypotheses was seen as a promising way forward.
Focusing alone on the relationship between childhood leukaemia and nuclear installations 
is unlikely to help. Emphasis should be placed on better understanding of the causes of child-
hood leukaemia and how these causes are distributed among the childhood population. Ways 
forward have been pointed out, trying to integrate hypotheses and modern biological and 
experimental techniques, if possible. Research strategies need to take full account of the exist-
ing body of evidence, so that duplication of research is avoided and the focus is upon promis-
ing avenues of investigation.
The following recommendations can be highlighted from the MELODI Workshop:
 (a)  The surveillance of childhood leukaemia incidence should be continued, not only 
around nuclear installations.
 (b)  No specific epidemiological study design is recommended. Various approaches 
are potentially fruitful as long as they are based on prior hypotheses, provide 
accurate exposure estimates and avoid major biases.
 (c)  Setting up of new studies on childhood leukaemia near nuclear installations is 
not necessary unless they include new features, e.g. a close link to research into 
the pathogenesis of childhood leukaemia. Collection of bio-specimens (e.g. cord 
blood or neo-natal blood spots) is important to allow research of biomarkers, and 
their analysis should be done at appropriate time windows.
 (d)  Efforts should be made to harmonise exposure estimates (probably including the 
assessment of relevant incorporated radionuclides), to better characterise the popula-
tion with respect to demography, urban/rural status, life habits and sociologic factors, 
patterns of population mixing, as well as other potential environmental risk factors 
including ELF-EMF, proximity of chemical factories, petrol stations, highways, etc.
 (e)  Studies should distinguish between leukaemia subtypes, ensuring consistency of 
subgroup definitions across studies for comparability. Epigenetic/genetic profiles 
of childhood leukaemia should be used in conjunction with epidemiologic data.
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 (f)  The implementation of an international working group is recommended to better 
understand the variability of results between countries. This group would be a 
step forward to verifying the feasibility and pertinence of international pooling 
analysis. Specific aims of a pooled analysis are increasing statistical power to 
allow analyses of leukaemia subtypes, overcoming the problems of boundaries 
and harmonising the study designs.
 (g)  Prevalence of the preleukaemic clone (ETV6-RUNX1 and other translocations) 
has to be determined.
 (h)  Determining the relationship between leukaemia and the immune function is of 
major importance, especially regarding the hypothesis of an infectious cause. 
An urban–rural stratification of existing SNP array data should be done. Deep 
sequencing of the genomes of leukaemia cases should be extended to allow 
detecting potential viral sequences.
 (i)  The linkage between epidemiology and experimental science needs to be 
improved. Animal studies can improve our understanding of the male : female 
ratio and the effects of birth weight, susceptibility targets, the role of immune 
system, and normal haematopoiesis and early stages of leukaemia development.
Activities have to be coordinated on a multi-national level. The European platform on low-
dose research MELODI should assist in bringing scientists from different disciplines closer 
together, in interaction with international research consortia that already exist.
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